Tessaric acid derivatives induce G2/M cell cycle arrest in human solid tumor cell lines

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 17, 2009, Pages 6251-6256

  León, Leticia G ^a,b   Donadel, Osvaldo J ^c   Tonn, Carlos E ^c   Padrón, José M ^a,b  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b Facultad de Ciencias Farmacéuticas y Bioquímicas   (Spain)

^c UNIVERSIDAD NACIONAL DE SAN LUIS   (Argentina)

Author keywords

Antitumor drugs; Cell cycle arrest; Michael acceptors; Sesquiterpenes; Tessaric acid

Indexed keywords

FLUOROURACIL; ILICIC ACID; IRINOTECAN; SESQUITERPENE DERIVATIVE; TESSARIC ACID; TESSARIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; HELA CELL; HUMAN; HUMAN CELL; IC 50; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REACTION ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; HUMANS; NEOPLASMS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SESQUITERPENES;

EID: 68649089752     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.07.053     Document Type: Article

References (19)

1. Newman D.J. J. Med. Chem. 51 (2008) 2589
2. Newman D.J., and Cragg G.M. J. Nat. Prod. 70 (2007) 461
3. Butler M.S., and Newman D.J. Prog. Drug. Res. 65 (2008) 3
4. Picman A.K. Biochem. Syst. Ecol. 14 (1986) 256
5. McDonald L.A., Barbieri L.R., Bernan V.S., Janso J., Lassota P., and Carter G.T. J. Nat. Prod. 67 (2004) 1565
6. Donadel O.J., Guerreiro E., María A.O., Wendel G., Enriz R.D., Giordano O.S., and Tonn C.E. Bioorg. Med. Chem. Lett. 15 (2005) 3547
7. Guerreiro E., Kavka J., Giordano O.S., and Gros E.G. Phytochemistry 18 (1979) 1235
8. Donadel O.J., García E.E., Guerreiro E., and Tonn C.E. An. Asoc. Quim. Argent. 86 (1998) 90
9. Donadel O.J., Guerreiro E., and Ardanaz C.E. Rapid Commun. Mass Spectrom. 15 (2001) 164
10. Kurina Sanz M.B., Donadel O.J., Rossomando P.C., Tonn C.E., and Guerreiro E. Phytochemistry 44 (1997) 897
11. Skehan P., Storeng P., Scudeiro D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., and Boyd M.R. J. Natl. Cancer Inst. 82 (1990) 1107
12. Miranda P.O., Padrón J.M., Padrón J.I., Villar J., and Martín V.S. ChemMedChem 1 (2006) 323
13. Tetko I.V., Gasteiger J., Todeschini R., Mauri A., Livingstone D., Ertl P., Palyulin V.A., Radchenko E.V., Zefirov N.S., Makarenko A.S., Tanchuk V.Y., and Prokopenko V.V. J. Comput. Aid. Mol. Des. 19 (2005) 453
14. Padrón J.M., and Peters G.J. Invest. New Drugs 24 (2006) 195
15. Pizao P.E., Peters G.J., van Ark-Otte J., Smets L.A., Smitskamp-Wilms E., Winograd B., Pinedo H.M., and Giaccone G. Eur. J. Cancer 29A (1993) 1566
16. Potashman M.H., and Duggan M.E. J. Med. Chem. 52 (2009) 1231
17. León L.G., Carballo R.M., Vega-Hernández M.C., Miranda P.O., Martín V.S., Padrón J.I., and Padrón J.M. ChemMedChem 3 (2008) 1740
18. Córdova I., León L.G., León F., San Andrés L., Luis J.G., and Padrón J.M. Eur. J. Med. Chem. 41 (2006) 1327
19. Pungitore C.R., León L.G., García C., Martín V.S., Tonn C.E., and Padrón J.M. Bioorg. Med. Chem. Lett. 17 (2007) 1332